Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension

NCT06129240 is registered in ClinicalTrials.gov with Liquidia Technologies, Inc. as lead sponsor.

NCT NCT06129240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06129240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in Pulmonary Hypertension
Lead sponsor
Liquidia Technologies, Inc.
Phase
Observational
Overall status
Recruiting
Start date
December 28, 2023
Completion date
February 8, 2028
Enrollment
80 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, pulmonary hypertension